Chai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery
Novartis will gain access to Chai Discovery’s AI design models and platform to support therapeutic antibody discovery across multiple targets
Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Novartis to advance the discovery of therapeutic antibodies using artificial intelligence.
Under the collaboration, Novartis will gain access to Chai’s latest AI models, including the Chai-3 model, to support Novartis in the discovery of antibodies for therapeutic programs across multiple targets.
The agreement builds on more than a year of technical engagement between the two companies, including early access to Chai’s next-generation folding model last spring. After tracking Chai’s progress in AI-driven molecular design over the past year, Novartis and Chai are now extending their work together to support broader deployment across multiple therapeutic programs.
